
October 2 marks "Senior Citizens' Day" in South Korea—a statutory observance intended to foster respect for older adults and highlight the health challenges of an aging society. Among the most prevalent chronic conditions affecting older populations are high blood pressure and osteoarthritis. While the two diseases frequently coexist, the precise biological mechanism linking hypertension to accelerated joint degradation has long remained elusive.
A joint research team from Inje University and Chonnam National University published findings on October 1 in the journal Science, identifying for the first time a neuroendocrine pathway through which high blood pressure exacerbates osteoarthritis. The study reframes osteoarthritis from a simple disease of mechanical joint wear into a systemic condition tied to overall vascular and endocrine health, offering fresh clues for dual-targeted therapeutic strategies.
The Vasopressin-AVPR1A Signaling Pathway
To investigate the connection between hypertension and joint damage, the researchers analyzed data from the Korea National Health and Nutrition Examination Survey alongside experimental mouse models of induced high blood pressure.
Their analysis revealed that high blood pressure significantly speeds the progression of osteoarthritis through arginine vasopressin (AVP)—a brain-derived hormone responsible for regulating fluid balance and blood pressure. Under hypertensive conditions, systemic levels of vasopressin surge. Crucially, as joint cartilage ages or sustains damage, chondrocytes (cartilage cells) express significantly higher levels of AVPR1A, the primary receptor for vasopressin.
When elevated vasopressin binds to these overexpressed AVPR1A receptors in aging cartilage, it triggers an overproduction of enzymes that break down the cartilage matrix. When the research team genetically deleted or pharmacologically inhibited the AVPR1A receptor in hypertensive mice, cartilage destruction was markedly reduced. This indicates that high blood pressure does not merely exert physical stress on joints; it actively drives tissue breakdown via a specific hormonal signaling pathway.
Expanding the Paradigm: The "Brain-Hormone-Joint" Axis
"In young individuals with healthy cartilage, high blood pressure alone does not cause arthritis," explained Ryu Je-hwang, a professor at Chonnam National University’s School of Dentistry and co-first author of the study. "However, once aging or prior joint trauma upregulates the receptors that detect vasopressin, high blood pressure acts as a trigger that accelerates cartilage breakdown."
The discovery expands the classical view of osteoarthritis as a localized joint disorder into a broader systemic paradigm. "This study is the first to break the long-held notion that arthritis is strictly a disease of the joints, demonstrating concrete evidence that brain-derived hormones regulate joint health," Ryu added. "It shifts the research focus from inside the joint capsule to a whole-body 'brain-hormone-joint' axis, paving the way for treating age-related joint diseases as systemic health issues."
Despite the breakthrough, experts caution against concluding that antihypertensive medications or receptor blockers can immediately prevent or cure osteoarthritis.
Lee Sang-yeol, a professor of endocrinology and metabolism at Kyung Hee University College of Medicine and the Digital Health Center, noted: "This study provides a valuable framework for understanding osteoarthritis beyond mechanical wear by linking it to systemic metabolic and endocrine regulation. However, the efficacy and safety of targeting the AVPR1A receptor must be rigorously validated through prospective human clinical trials."
Professor Ryu similarly emphasized that because the findings rely on human observational data and rodent models, extensive clinical research will be required to confirm therapeutic outcomes in human patients.
